

DISCUSSION

Back to reality – the (copy)-cat is out of the bag!



- How do we talk about “external controls” in MASH or other liver disease trials
 - If constructed* from registries or natural history studies
 - If constructed from previous trials’ placebo arm patients
 - If constructed from EHR and/or claims data
 - If completely “synthesized” *in silico*

*define “constructed”

Can AI approaches increase RCT efficiency?

Beyond DT's

Virtual patients, digital twins and causal disease models: Paving the ground for *in silico* clinical trials

Philippe Moingeon^{1,*}, Marylore Chenel², Cécile Rousseau³, Emmanuelle Voisin³,
Mickael Guedj¹

Drug Discovery Today • Volume 28, Number 7 • July 2023

Quantitative Systems Pharmacology

AI-ENHANCED QSP

